- Home
- ACRE vs LXRX Comparison
ACRE vs LXRX Comparison
Compare ACRE & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- LXRX
- Stock Information
- Founded
- ACRE 2011
- LXRX 1995
- Country
- ACRE United States
- LXRX United States
- Employees
- ACRE N/A
- LXRX N/A
- Industry
- ACRE Real Estate Investment Trusts
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- ACRE Real Estate
- LXRX Health Care
- Exchange
- ACRE Nasdaq
- LXRX Nasdaq
- Market Cap
- ACRE 278.1M
- LXRX 283.7M
- IPO Year
- ACRE 2012
- LXRX 2000
- Fundamental
- Price
- ACRE $4.96
- LXRX $0.71
- Analyst Decision
- ACRE Hold
- LXRX Buy
- Analyst Count
- ACRE 8
- LXRX 2
- Target Price
- ACRE $6.60
- LXRX $4.00
- AVG Volume (30 Days)
- ACRE 746.6K
- LXRX 4.2M
- Earning Date
- ACRE 02-12-2025
- LXRX 03-10-2025
- Dividend Yield
- ACRE 18.14%
- LXRX N/A
- EPS Growth
- ACRE N/A
- LXRX N/A
- EPS
- ACRE N/A
- LXRX N/A
- Revenue
- ACRE $87,802,000.00
- LXRX $5,229,000.00
- Revenue This Year
- ACRE N/A
- LXRX $842.94
- Revenue Next Year
- ACRE $8.58
- LXRX $19.76
- P/E Ratio
- ACRE N/A
- LXRX N/A
- Revenue Growth
- ACRE 7874.75
- LXRX 886.60
- 52 Week Low
- ACRE $4.88
- LXRX $0.62
- 52 Week High
- ACRE $7.99
- LXRX $2.83
- Technical
- Relative Strength Index (RSI)
- ACRE 29.49
- LXRX 43.33
- Support Level
- ACRE $4.91
- LXRX $0.66
- Resistance Level
- ACRE $5.15
- LXRX $0.97
- Average True Range (ATR)
- ACRE 0.19
- LXRX 0.07
- MACD
- ACRE -0.07
- LXRX -0.00
- Stochastic Oscillator
- ACRE 6.53
- LXRX 16.13
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.